Please login to the form below

Not currently logged in
Email:
Password:

defibrotide

This page shows the latest defibrotide news and features for those working in and with pharma, biotech and healthcare.

Jazz Pharma bags FDA approval for rare disease drug

Jazz Pharma bags FDA approval for rare disease drug

The US regulator has approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) as a complication of a haematological stem cell transplant (HSCT).

Latest news

  • SMC: Celgene's Abraxane 'too expensive' for Scotland SMC: Celgene's Abraxane 'too expensive' for Scotland

    Drugs that received positive opinions included Janssen's Invokana (canagliflozin) for type 2 diabetes, Jazz Pharmaceuticals' Defitelio (defibrotide) for liver disease, GSK's respiratory combination Relvar Ellipta (fluticasone furoate / vilanterol)

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    The $57 per share deal gives Jazz an immediate boost in its ex-US business as well as access to Gentium's Defitelio (defibrotide) drug for the treatment of severe hepatic

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    Gentium expects EMA rejection for defibrotide. Negative feedback for drug’ s use in liver condition associated with stem cell transplantation. ... Gentium is expecting the European Medicines Agency (EMA) to turn down its investigational medicine

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic veno-occlusive disease (approved EU/ NDA US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics